{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:20:31Z","timestamp":1793017231620,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of low-dose rituximab (RTX) in the treatment of pemphigus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov to identify eligible studies. Primary efficacy outcomes included complete remission (CR), relapse rates, time to disease control (TDC), time to CR, and cumulative corticosteroid dose. Safety outcomes were assessed by meticulously documenting adverse events (AEs) and concomitant medications reported in each study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final analysis incorporated five comparative studies and nine single-arm studies investigating the efficacy and safety outcomes of low-dose RTX. Comparative data revealed no statistically significant differences between the high-dose and low-dose RTX groups in CR, relapse rates, TDC, time to CR, and cumulative corticosteroid dose. In single-arm studies, pooled CR and relapse rates were 63.2% and 28.6%, respectively. No fatal events were reported; however, severe AEs, including pneumonia and sepsis, were documented in the low-dose RTX cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-dose RTX exhibited comparable clinical efficacy to high-dose RTX regimens in pemphigus management. However, clinicians should remain vigilant for potential AEs associated with low-dose RTX infusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1605243","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:25:26Z","timestamp":1753421126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Si-Han","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Gang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.02.005","article-title":"Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy","volume":"18","author":"Buonavoglia","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: A review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0283","article-title":"Persistent B lymphocyte depletion after an ultralow dose of rituximab for pemphigus vulgaris","volume":"28","author":"Lazzarotto","year":"2018","journal-title":"J investigational allergology Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta dermato-venereologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31354","article-title":"Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis","volume":"35","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatol (Baltimore Md)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J surgery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.08.015","article-title":"Use of the GRADE approach in systematic reviews and guidelines","volume":"123","author":"Granholm","year":"2019","journal-title":"Br J Anaesth"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2302071","DOI":"10.1080\/09546634.2024.2302071","article-title":"The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study","volume":"35","author":"Zhou","year":"2024","journal-title":"J Dermatol Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.47009\/jamp.2024.6.1.189","article-title":"Efficacy and safety of low-dose rituximab in the treatment of immunobullous disorders","volume":"6","author":"Parvathi","year":"2024","journal-title":"Int J Acad Med Pharmacy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2014","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14349","article-title":"A randomized study comparing full dose and half dose of rituximab in relapsing pemphigus patients","volume":"33","author":"Saleh","year":"2020","journal-title":"Dermatologic Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15213","article-title":"Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus","volume":"47","author":"Singh","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_1078_14","article-title":"Low-dose rituximab as an adjuvant therapy in pemphigus","volume":"83","author":"Gupta","year":"2017","journal-title":"Indian J dermatology venereology leprology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1187","article-title":"Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12571","article-title":"Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients","volume":"59","author":"Robinson","year":"2018","journal-title":"Australas J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1727440","article-title":"Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study","volume":"20","author":"Russo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20819","article-title":"Ultralow-dose rituximab in pemphigus: a single-centre experience","volume":"186","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","volume":"94","author":"Cho","year":"2014","journal-title":"Acta dermato-venereologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1801974","article-title":"The efficacy of rituximab in patients with mucous membrane pemphigoid","volume":"33","author":"Amir Dastmalchi","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.10.018","article-title":"Low-dose rituximab for bullous pemphigoid. Protocol and single-center experience","volume":"114","author":"Su\u00e1rez-Caranto\u00f1a","year":"2023","journal-title":"Actas dermo-sifiliograficas"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16668","article-title":"Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab","volume":"50","author":"Chen","year":"2023","journal-title":"J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib13010004","article-title":"Is it time to reconsider rituximab dosing regimens for pemphigus vulgaris","volume":"13","author":"Ciolfi","year":"2024","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16145","article-title":"Sustainable effect of ultra-low dose rituximab for mild-to-moderate pemphigus vulgaris: A case report","volume":"48","author":"Wang","year":"2021","journal-title":"J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1506","article-title":"A study of ultra-low dose rituximab as adjuvant to standard of care in treatment of significant and extensive pemphigus vulgaris: a case series","volume":"91","author":"Patel","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.136832","article-title":"Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus","volume":"80","author":"Londhe","year":"2014","journal-title":"Indian J dermatology venereology leprology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12814","article-title":"Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab","volume":"32","author":"Cho","year":"2019","journal-title":"Dermatologic Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849790","article-title":"The diversity of serum anti-DSG3 IgG subclasses has a major impact on pemphigus activity and is predictive of relapses after treatment with rituximab","volume":"13","author":"Golinski","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better","volume":"311","author":"Balighi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15249","article-title":"Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation","volume":"35","author":"Balighi","year":"2022","journal-title":"Dermatologic Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1605243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:25:27Z","timestamp":1753421127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1605243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1605243"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1605243","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1605243"}}